Gri bio engages b2i digital to deploy cutting-edge engagement campaign

La jolla, california--(newsfile corp. - august 29, 2023) - gri bio, inc. (nasdaq: gri), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer t (nkt) cells, today announced it has engaged b2i digital, inc. ("b2i") to execute an innovative digital engagement and awareness program. b2i brings together decades of experience from public relations, investment banking, and digital marketing to advise on and develop marketing campaigns to target appropriate stakeholders.
GRI Ratings Summary
GRI Quant Ranking